4-DAY CE Conference - CHICAGO, IL - April 24-27, 2024

1,097
799.00
Package Price Ends 04/24/2024

Enhance your expertise with this dynamic 4-day, knowledge-building program. Plus, you’ll be able to apply everything you learn immediately in your practice. 

Location: Chicago Marriott Schaumburg    
50 N Martingale Rd    
Schaumburg, IL 60173 

Conference Dates:  April 24-27, 2024 

4-Day CE Conference Includes: 

Days 1 & 2: Pharmacology Update    
Schedule: 8 AM – 4 PM (includes breaks)    
Contact Hours: 12 (12 Rx)    
Presenter: Dr. Wendy Wright 

  • Case study Approach to Asthma Management: Focus on Pharmacology and Guidelines 
  • Meeting the Challenge of Fibromyalgia Management: Multimodal Therapy is Essential 
  • Covid-19 Updates Part 1: Management of Long Covid 
  • Covid-19 Updates Part 2: Drug-Drug Interactions and The Impact on Patients with Covid and Other Chronic Conditions 
  • Pharmacotherapeutic Options for Lipid Management: Evolving the Science 
  • Diabetes Update: Latest in Pharmacotherapeutic Treatment Options for Primary Care 
  • Pharmacology and Obesity Management: Discussion of Medications and Use 
  • Case based approach to hypertension management: Combination Therapy is Essential 

Day 3: Skin Health Across the Lifespan: A Guide to Dermatology    
Schedule: 8 AM – 4 PM (includes breaks)    
Contact hours: 6 (0 Rx)    
Presenter: Dr. Victor Czerkasij 

Learn a variety of tips and tools to boost knowledge and skills needed for primary care practice. Topics will be presented in four parts by dermatology expert Victor Czerkasij, DNP, MA, MS, FNP-BC. 

  • Pediatric Dermatology 
  • Geriatric Dermatology 
  • Skin Cancer and Melanoma 
  • Emergency! Cutaneous Manifestations of Internal Disease

Day 4: 8-hour DEA Registration and Controlled Substance Prescribing Course   
Schedule: 8 AM – 5:30 PM (includes breaks)    
Contact hours: 8 (8 Rx)    
Presenter: Dr. Sally Miller

Controlled Substance Prescribing meets the 8-hour federal requirement to renew DEA registration as of 6/27/23 as mandated by Section 1262 of the Consolidated Appropriations Act, 2023. 

This 8-hour program meets the requirements of the Consolidated Appropriations Act, 2023, which requires that effective June 27, 2023 all prescribers of controlled substances must have a minimum of 8 hours of continuing education in the assessment and management of opioid or other substance use disorder in order to apply for or renew DEA registration. The program includes principles of pain management, opioid prescribing, opioid risk assessment, legislative issues, and management of opioid-use disorder with medically assisted therapy. Additionally, the program presents non-opioid controlled substance considerations, including psychostimulants, benzodiazepines, appetite suppressants, and sedative hypnotics. Indications, selection, and both assessment and management of use disorders is presented. Successful completion of this program complies with eligibility requirements for initial and renewal DEA registration, and meets most state-mandated requirements for opioid prescribing. 

Objectives: 

  • Describe the key steps in pain reception and perception.  
  • Compare and contrast mechanisms of opiate and non-opiate pain agents.  
  • Discuss CDC recommendations and legislative considerations in opioid prescribing. 
  • Analyze elements of opioid risk assessment.  
  • Evaluate indications for and elements of medically assisted therapy.  
  • Analyze indications for benzodiazepine therapy and strategies to minimize abuse potential.  
  • Evaluate mechanisms and abuse potential of psychostimulants.  
  • Compare and contrast controlled and non-controlled options for insomnia.

Note: To receive a certificate of attendance, full attendance on all days is required.